The present invention relates to novel promoters, including transcription
regulator regions, for the mouse VEGFR-2 receptor, isolated
polynucleotides comprising such promoters, nucleic acid constructs
comprising such promoters operatively linked to genes encoding a gene
product, such as, a reporter, a protein, polypeptide, hormone, ribozyme,
or antisense RNA, recombinant cells comprising such nucleic acid
constructs, screening for therapeutic drugs using such cells (e.g.,
screening for compounds that modulate VEGFR-2-mediated angiogenesis), and
endothelial tissue-specific gene expression using these novel promoter
sequences.
